



Date: 29-05-2026

The General Manager  
Department of Corporate Services – CRD  
BSE LIMITED PhirozeJeejeebhoy Towers  
Dalal Street, Mumbai 400 001.

Ref:- Scrip Code : 526139

Dear Sir/Madam,

Subject: Outcome of Board Meeting and submission of Audited Financial Results for the fourth quarter and financial year ended March 31, 2026

This has reference to our letter dated May 13, 2026, The Board of Directors of the Company at their meeting held on May 29, 2026 have resolved as follows:

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:

- a) Audited Financial Results (Standalone and Consolidated) of the Company for the fourth quarter and financial year ended March 31, 2026.
- b) Report of the Auditors on the Audited Financial Results, both for (Standalone and Consolidated) financial statements for the financial year ended March 31, 2026.
- c) Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Consolidated and Standalone Financial Statements for the Financial Year ended March 31, 2026.

The meeting of the Board of Directors of the Company commenced at 11.00 AM and concluded at 11.30 AM.

We kindly request you to take the above said on record.

Thanking You,

Yours faithfully

For TRANSGENE BIOTEK LIMITED

DR K KOTESWARA RAO  
MANAGING DIRECTOR



May 29, 2026

The General Manager  
Department of Corporate Services – CRD,  
Bombay Stock Exchange Limited (BSE),  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai 400 001.

Dear Sir/Madam,

Scrip Code: 526139

Sub: Declaration regarding Auditor's Report with unmodified opinion.

Ref: Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations.

With reference to the above, we hereby confirm and declare that the Company has received audit report with unmodified opinion for both standalone and consolidated audited financial results of the Company for the financial year ended March 31, 2026 from the statutory auditors. M/s. Vasavi & Co, Chartered Accountants of the Company (Membership No: 249259) vide Independent Auditors Report dated May 29, 2026.

We request you to kindly take the above mentioned information on your records.

Thanking you.

Yours faithfully,  
For TRANSGENE BIOTEK LIMITED

DR K KOTESWARA RAO  
CHAIRMAN & MANAGING DIRECTOR



# M/S VASAVI & CO

## Chartered Accountants

---

### **Independent Auditor's Report on Audited Standalone Quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To**  
**The Board of Directors of**  
**M/s TRANSGENE BIOTEK LTD**

#### **Report on the audit of the Standalone Financial Results**

#### **Opinion**

We have audited the accompanying standalone quarterly financial results of M/s Transgene Biotek Limited (the company) for the quarter ended 31/03/2026 and the year to date results for the period from 01/04/2025 to 31/03/2026, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the quarter ended 31/03/2026 as well as the year to date results for the period from 01/04/2025 to 31/03/2026

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Management's Responsibilities for the Standalone Financial Results**

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian



## M/S VASAVI & CO Chartered Accountants

---

Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are

based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matters**

The statement includes the financial results for the half year ended 31/03/2026, being the balancing figures between the audited figures in respect of the full financial year and published unaudited year to date figures up to the first half of the current financial year, which were subject to limited review by us.

**For VASAVI & CO,  
Chartered Accountants  
FRN 020965S**

*G.R.L. Vasavi*

**(CA VASAVI GOLLAPUDI)  
Proprietor  
MRN 249259**



**UDIN for this document is: 26249259HHRIFB9986**

**Place: Hyderabad**

**Date: 29/05/2026**



# M/S VASAVI & CO

## Chartered Accountants

---

### **Independent Auditor's Report On Quarterly and year to date Audited Consolidated Financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To**  
**The Board of Directors,**  
**M/s Transgene Biotek Limited**  
**Hyderabad**

#### **Report on the Audit of Consolidated Financial Results**

#### **Opinion**

We have audited the accompanying consolidated annual financial results of Transgene Biotek Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended 31/03/2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the statement,

- (i) include the annual financial results of the following entities
  - Transgene Biotek HK Ltd - Subsidiary
- (ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (iii) give a true and fair view in conformity with the applicable Indian accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit after tax and other comprehensive income and other financial information of the Group for the quarter ended March 31, 2026 and for the period from April 1, 2025 to March 31, 2026.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.



### **Board of Directors' Responsibilities for the Consolidated Financial Results**

These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information of the Group including its associates and jointly controlled entities in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



## M/S VASAVI & CO Chartered Accountants

---

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

### **Other Matters**

our opinion and according to the information and explanations given to us by the Board of Directors, this Financial Statements/Financial Results/financial information are not material to the Group. As the subsidiary M/s Transgene Biotek HK Ltd is not in operations, the books of accounts have not been audited for many years. The company is not recognizing foreign gain or loss, as there are no transactions incurred since many years. The last available figures are of 2015-16 and the same are being carried forward since then for consolidation of financials.



# M/S VASAVI & CO

## Chartered Accountants

---

Our opinion on the consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the Financial Results/financial information certified by the Board of Directors.

The Financial Results include the results for the quarter ended 31/03/2025 being the balancing figure between the audited figures in respect of the full financial year and the published audited year to date figures up to the third quarter of the current financial year.

**For VASAVI & CO,  
Chartered Accountants  
FRN 020965S**

*G.R.L. Vasavi*



**(CA VASAVI GOLLAPUDI)  
Proprietor  
MRN 249259**

**UDIN for this document is: 26249259HHRIFB9986**

**Place: Hyderabad  
Date: 29/05/2026**


**TRANSGENE BIOTEK LIMITED**

Plot No:69 &amp; 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2026**

(In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year to date figures Previous year ended
		31-03-2026 (Audited)	31-12-2025 (Unaudited)	31-03-2025 (Audited)	31-03-2026 (Audited)	31-03-2025 (Audited)
1	Revenue from operations	5.45	5.45	7.65	21.12	26.07
2	Other income (net)	14.99	0.00	4.38	14.99	78.35
3	<b>Total income (1 + 2)</b>	<b>20.43</b>	<b>5.45</b>	<b>12.03</b>	<b>36.11</b>	<b>104.42</b>
4	<b>EXPENSES</b>					
	Cost of materials consumed	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	3.38	3.31	6.34	14.73	30.78
	Finance costs	27.68	27.35	19.12	106.02	24.30
	Depreciation and amortisation expense	4.98	4.98	2.35	19.91	9.32
	Other expenses	30.09	7.18	55.53	60.74	107.62
	<b>Total expenses</b>	<b>66.13</b>	<b>42.82</b>	<b>83.34</b>	<b>201.40</b>	<b>172.03</b>
5	<b>Profit before exceptional items, share of profit from associate &amp; joint venture and tax (3 - 4)</b>	<b>-45.70</b>	<b>-37.38</b>	<b>-71.31</b>	<b>-165.29</b>	<b>-67.61</b>
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00
7	<b>Profit before tax (5 - 6)</b>	<b>-45.70</b>	<b>-37.38</b>	<b>-71.31</b>	<b>-165.29</b>	<b>-67.61</b>
8	<b>Tax expense</b>					
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00
	<b>Total tax expense</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
9	<b>Profit for the year (7 - 8)</b>	<b>-45.70</b>	<b>-37.38</b>	<b>-71.31</b>	<b>-165.29</b>	<b>-67.61</b>
10	<b>Other comprehensive income</b>					
	A Items that will not be reclassified subsequently to profit or loss					
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00
	<b>Total other comprehensive income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
11	<b>Total comprehensive income for the year (9 + 10)</b>	<b>-45.70</b>	<b>-37.38</b>	<b>-71.31</b>	<b>-165.29</b>	<b>-67.61</b>
12	<b>Earnings per equity share</b>					
	(Equity shares, par value of Rs. 10 each)	757.70	757.70	757.70	757.70	757.70
	Basic (Rs.)	(0.06)	(0.05)	(0.09)	(0.22)	(0.09)
	Diluted (Rs.)	(0.06)	(0.05)	(0.09)	(0.22)	(0.09)

**Notes:**

- 1 SECURITIES APPELLATE TRIBUNAL (SAT): Our appeal against SEBI was listed for hearing on 1st April 2026 and adjourned to 14th July 2026.
- 2 APPELLATE TRIBUNAL (ED), NEW DELHI: Our appeal against the order passed by ED Adjudication Officer was heard on 13th April and posted for further hearing on 23rd July 2026.
- 3 SBIRI / BIRAC: There has been no further communication from BIRAC subsequent to the last board meeting on 14th November 2025.
- 4 CUSTOMS & EXCISE DEPARTMENT: There has been no further development on this matter since the last board meeting
- 5 NCLT: Our matter came up for hearing on 13th April 2026 and adjourned for next hearing on 8th July 2026
- 6 COMPLAINTS: No. of complaints pending at the beginning of the quarter – 0; received complaints during the quarter – 0
  
- 7 AUDIT REVIEW: The auditors have carried out a limited review of the financial results for the quarter ended 31st March 2026 and following the approval by the audit committee, it has been passed by the Board of Directors at the meeting held on 29th May 2026.

**For TRANSGENE BIOTEK LIMITED**



**Dr.K.Koteswara Rao**  
**Managing Director**

**Date: 29/05/2026**  
**Place:Hyderabad**



## TRANSGENE BIOTEK LIMITED

69 & 70, IDA Bollaram, Sangareddy District - 502325, Telangana

CIN NO: L85195TG1990PLC011065

(In Lakhs)

### Standalone Statement of assets and liabilities

PARTICULARS	As at 31 March 2026	As at 31 March 2025
<b>ASSETS</b>		
<b>NON-CURRENT ASSETS</b>		
(a) Property, plant and equipment	309.30	328.50
(b) Right of Use Assets	-	-
(c) Capital work-in-progress	-	-
(d) Investment Properties	-	-
(e) Goodwill	-	-
(f) Other intangible assets	467.03	467.75
(g) Intangible assets under development	186.77	186.77
(h) Biological Assets Other Than Bearer Plants	-	-
(i) Financial assets	-	-
(i) Investments	9.49	9.50
(ii) Trade Receivables	-	-
(iii) Loans	2302.04	2302.04
(iv) Other Financial Assets	-	-
(j) Deferred Tax Assets (Net)	-	-
(k) Other non-current assets	-	-
<b>SUB-TOTAL</b>	<b>3274.63</b>	<b>3294.55</b>
<b>CURRENT ASSETS</b>		
(a) Inventories	3.40	3.40
(b) Financial assets	-	-
(i) Investments	-	-
(ii) Trade Receivables	-	-
(iii) Cash and cash equivalents	6.07	28.43
(iv) Bank Balances other than (iii) above	0.01	0.01
(v) Loans	-	-
(vi) Other Financial Assets	-	-
(c) Current Tax Assets (Net)	-	-
(d) Other current assets	92.37	93.74
<b>SUB-TOTAL</b>	<b>101.84</b>	<b>125.57</b>
Non-Current Assets Classified as Held for Sale	-	-
<b>TOTAL ASSETS</b>	<b>3376.47</b>	<b>3420.12</b>

EQUITY AND LIABILITIES	As at 31 March 2026	As at 31 March 2025
<b>EQUITY</b>		
Equity share capital	7577.00	7577.00
Other equity	-8496.98	-8331.69
<b>SUB-TOTAL</b>	<b>-919.98</b>	<b>-754.69</b>
<b>LIABILITIES</b>		
<b>NON-CURRENT LIABILITIES</b>		
(a) Financial Liabilities		
(i) Borrowings	680.08	610.29
(ii) Trade Payable	0.00	0.00
(iii) Other financial liabilities	0.00	0.00
(b) Provisions	2302.04	2302.04
(c) Deferred tax liabilities (net)	0.00	0.00
(d) Other non-current liabilities	0.00	0.00
<b>SUB-TOTAL</b>	<b>2982.12</b>	<b>2912.33</b>
<b>CURRENT LIABILITIES</b>		
(a) Financial liabilities		
(i) Borrowings	1033.60	841.70
(ii) Trade payables	6.83	159.34
(iii) Other financial liabilities	0.00	0.00
(b) Provisions	133.21	134.82
(c) Other current liabilities	140.69	126.62
(d) Current tax liabilities (net)	0.00	0.00
<b>SUB-TOTAL</b>	<b>1314.34</b>	<b>1262.48</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>3376.47</b>	<b>3420.12</b>
<b>Corporate information and significant accounting policies</b>		
The accompanying notes form an integral part of the Consolidated financial statements		

For TRANSGENE BIOTEK LIMITED

**Dr.K.Koteswara Rao**  
Managing Director

Date: 29/05/2026

Place:Hyderabad

**TRANSGENE BIOTEK LIMITED**

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

**Standalone Statement of Cash Flows for the year ended 31st March 2026**

(In Lakhs)

Particulars	For the year ended March 31, 2026		For the year ended March 31, 2025	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Profit before tax		-165.29		-67.61
<u>Adjustments for :</u>				
Depreciation and amortisation expense	19.91		9.32	
Finance costs	106.02		24.30	
Amortisation of government grant	0.00		-17.54	
Supplier Advances Written off	0.00			
Bad debts written off				
Profit or loss on sale of Fixed asset/Shares	-14.99			
Other Non cash Expenses				
<b>Operating profit before working capital changes</b>		<b>-54.35</b>		<b>-51.52</b>
<u>Changes in working capital:</u>				
<i>Adjustments for (increase) / decrease in operating assets:</i>				
Trade receivables				
Other non-current assets				
Other Current assets	1.36		12.21	
Inventories	0.00		-0.01	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>				
Trade payables	-152.51		139.03	
Provision (CL)	-1.61		-48.07	
Borrowing (CL)	191.90		-50.45	
Other financial liabilities	0.00			
Other current liabilities	14.07		118.40	
Provision (NCL)	0.00			
<b>Cash generated from operations</b>		<b>-1.13</b>		<b>119.58</b>
Net income tax paid				
<b>Net cash flow from operating activities (A)</b>		<b>-1.13</b>		<b>119.58</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Capital expenditure on fixed assets, including capital advances	0.00		-169.95	
Investments			0.00	
Proceeds from sale of fixed assets/shares	15.00		0.00	
<b>Net cash (used in) / flow from investing activities (B)</b>		<b>15.00</b>		<b>-169.95</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds from issue of equity shares				
Finance costs	-106.02		-24.30	
Proceeds from Borrowings	69.79		600.00	
Payment of Borrowing	0.00		-497.66	
<b>Net cash flow (used in) financing activities (C)</b>		<b>-36.23</b>		<b>78.03</b>
<b>Net (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>-22.36</b>		<b>27.66</b>
<b>Cash and cash equivalents at the beginning of the year</b>		<b>28.43</b>		<b>0.77</b>
Effect of exchange differences on translation of foreign currency Cash and cash equivalents				
<b>Cash and cash equivalents at the end of the year</b>		<b>6.07</b>		<b>28.43</b>

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao  
Managing Director

Date: 29/05/2026  
Place:Hyderabad

**TRANSGENE BIOTEK LIMITED**

Notes forming part of the Standalone financial statements

Other expenses	(In Lakhs)
Particulars	For the Period ended on 31st March 2026
Advertisement	0.13
Bank charges	0.00
BSNL Fiber net	0.02
Contractual expenses	0.27
Conveyance Expenses	0.06
Directors sitting fee	0.15
E Voting charges	0.17
Legal and Professional Charges	23.78
Miscllaneous Expenses	0.01
Municipal tax	2.46
Office Expenses	1.09
Postage and Courier Expenses	0.00
Printing and Stationary	0.00
Rates, taxes and duties	0.22
PCB Renewal	0.45
Telephone Expenses	0.02
Waste disposal Expenses	1.27
<b>Total</b>	<b>30.09</b>

For TRANSGENE BIOTEK LIMITED



**Dr.K.Koteswara Rao**  
**Managing Director**

Date: 29/05/2026

Place:Hyderabad



## TRANSGENE BIOTEK LIMITED

69 & 70, IDA Bollaram, Sangareddy District - 502325, Telangana

CIN NO: L85195TG1990PLC011065

(In Lakhs)

### Consolidated Statement of assets and liabilities

PARTICULARS	As at 31 March 2026	As at 31 March 2025
<b>ASSETS</b>		
<b>NON-CURRENT ASSETS</b>		
(a) Property, plant and equipment	309.30	328.50
(b) Right of Use Assets	-	-
(c) Capital work-in-progress	-	-
(d) Investment Properties	-	-
(e) Goodwill	-	-
(f) Other intangible assets	467.03	467.75
(g) Intangible assets under development	186.77	186.77
(h) Biological Assets Other Than Bearer Plants	-	-
(i) Financial assets	-	-
(i) Investments	9.49	9.50
(ii) Trade Receivables	-	-
(iii) Loans	13290.24	13290.24
(iv) Other Financial Assets	-	-
(j) Deferred Tax Assets (Net)	-	-
(k) Other non-current assets	-	-
<b>SUB-TOTAL</b>	<b>14262.83</b>	<b>14282.75</b>
<b>CURRENT ASSETS</b>		
(a) Inventories	3.40	3.40
(b) Financial assets	-	-
(i) Investments	-	-
(ii) Trade Receivables	0.84	0.84
(iii) Cash and cash equivalents	6.07	28.43
(iv) Bank Balances other than (iii) above	0.01	0.01
(v) Loans	-	-
(vi) Other Financial Assets	-	-
(c) Current Tax Assets (Net)	-	-
(d) Other current assets	92.37	93.74
<b>SUB-TOTAL</b>	<b>102.69</b>	<b>126.41</b>
Non-Current Assets Classified as Held for Sale	-	-
<b>TOTAL ASSETS</b>	<b>14365.51</b>	<b>14409.16</b>

EQUITY AND LIABILITIES	As at 31 March 2025	As at 31 March 2024
<b>EQUITY</b>		
Equity share capital	7577.00	7577.00
Other equity	-6739.30	-6574.01
<b>SUB-TOTAL</b>	<b>837.70</b>	<b>1002.99</b>
<b>LIABILITIES</b>		
<b>NON-CURRENT LIABILITIES</b>		
(a) Financial Liabilities		
(i) Borrowings	680.08	610.29
(ii) Trade Payable	0.00	0.00
(iii) Other financial liabilities	0.00	0.00
(b) Provisions	11522.14	11522.14
(c) Deferred tax liabilities (net)	0.00	0.00
(d) Other non-current liabilities	0.00	0.00
<b>SUB-TOTAL</b>	<b>12202.22</b>	<b>12132.43</b>
<b>CURRENT LIABILITIES</b>		
(a) Financial liabilities		
(i) Borrowings	1033.60	841.70
(ii) Trade payables	6.83	159.34
(iii) Other financial liabilities	11.26	11.26
(b) Provisions	133.21	134.82
(c) Other current liabilities	140.69	126.62
(d) Current tax liabilities (net)	0.00	0.00
<b>SUB-TOTAL</b>	<b>1325.60</b>	<b>1273.75</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>14365.51</b>	<b>14409.16</b>
<b>Corporate information and significant accounting policies</b>		
The accompanying notes form an integral part of the Consolidated financial statements		

For TRANSGENE BIOTEK LIMITED

**Dr.K.Koteswara Rao**  
**Managing Director**

**Date: 29/05/2026**

**Place:Hyderabad**



**TRANSGENE BIOTEK LIMITED**

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

**STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2026**

(In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year to date figures Previous year ended
		31-03-2026 (Audited)	31-12-2025 (Unaudited)	31-03-2025 (Audited)	31-03-2026 (Audited)	31-03-2025 (Audited)
1	Revenue from operations	5.45	5.45	7.65	21.12	26.07
2	Other income (net)	14.99	0.00	4.38	14.99	78.35
3	<b>Total income (1 + 2)</b>	<b>20.43</b>	<b>5.45</b>	<b>12.03</b>	<b>36.11</b>	<b>104.42</b>
4	<b>EXPENSES</b>					
	Cost of materials consumed	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	3.38	3.31	6.34	14.73	30.78
	Finance costs	27.68	27.35	19.12	106.02	24.30
	Depreciation and amortisation expense	4.98	4.98	2.35	19.91	9.32
	Other expenses	30.09	7.18	55.53	60.74	107.62
	<b>Total expenses</b>	<b>66.13</b>	<b>42.82</b>	<b>83.34</b>	<b>201.40</b>	<b>172.03</b>
5	<b>Profit before exceptional items, share of profit from associate &amp; joint venture and tax (3 - 4)</b>	<b>-45.70</b>	<b>-37.38</b>	<b>-71.31</b>	<b>-165.29</b>	<b>-67.61</b>
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00
7	<b>Profit before tax (5 - 6)</b>	<b>-45.70</b>	<b>-37.38</b>	<b>-71.31</b>	<b>-165.29</b>	<b>-67.61</b>
8	<b>Tax expense</b>					
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00
	<b>Total tax expense</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
9	<b>Profit for the year (7 - 8)</b>	<b>-45.70</b>	<b>-37.38</b>	<b>-71.31</b>	<b>-165.29</b>	<b>-67.61</b>
10	<b>Other comprehensive income</b>					
	A Items that will not be reclassified subsequently to profit or loss					
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00
	<b>Total other comprehensive income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
11	<b>Total comprehensive income for the year (9 + 10)</b>	<b>-45.70</b>	<b>-37.38</b>	<b>-71.31</b>	<b>-165.29</b>	<b>-67.61</b>
12	<b>Earnings per equity share</b>					
	(Equity shares, par value of Rs. 10 each)	757.70	757.70	757.70	757.70	757.70
	Basic (Rs.)	(0.06)	(0.05)	(0.09)	(0.22)	(0.09)
	Diluted (Rs.)	(0.06)	(0.05)	(0.09)	(0.22)	(0.09)

**Notes:**

- 1 SECURITIES APPELLATE TRIBUNAL (SAT): Our appeal against SEBI was listed for hearing on 1st April 2026 and adjourned to 14th July 2026.
- 2 APPELLATE TRIBUNAL (ED), NEW DELHI: Our appeal against the order passed by ED Adjudication Officer was heard on 13th April and posted for further hearing on 23rd July 2026.
- 3 SBIRI / BIRAC: There has been no further communication from BIRAC subsequent to the last board meeting on 14th November 2025.
- 4 CUSTOMS & EXCISE DEPARTMENT: There has been no further development on this matter since the last board meeting
- 5 NCLT: Our matter came up for hearing on 13th April 2026 and adjourned for next hearing on 8th July 2026
- 6 COMPLAINTS: No. of complaints pending at the beginning of the quarter – 0; received complaints during the quarter – 0
  
- 7 AUDIT REVIEW: The auditors have carried out a limited review of the financial results for the quarter ended 31st March 2026 and following the approval by the audit committee, it has been passed by the Board of Directors at the meeting held on 29th May 2026.

**For TRANSGENE BIOTEK LIMITED**



**Dr.K.Koteswara Rao**  
**Managing Director**

**Date: 29/05/2026**  
**Place:Hyderabad**

**TRANSGENE BIOTEK LIMITED**

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

**Consolidated Statement of Cash Flows for the year ended 31st March 2026**

(In Lakhs)

Particulars	For the year ended March 31, 2026		For the year ended March 31, 2025	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Profit before tax		-165.29		-67.61
<u>Adjustments for:</u>				
Depreciation and amortisation expense	19.91		9.32	
Finance costs	106.02		24.30	
Amortisation of government grant	-14.99		-17.54	
Supplier Advances Written off	0.00			
Bad debts written off				
Profit or loss on sale of Fixed asset				
Other Non cash Expenses				
<b>Operating profit before working capital changes</b>		<b>-54.35</b>		<b>-51.52</b>
<u>Changes in working capital:</u>				
<u>Adjustments for (increase) / decrease in operating assets:</u>				
Trade receivables				
Other non-current assets				
Other Current assets	1.36		12.21	
Inventories	0.00		-0.01	
<u>Adjustments for increase / (decrease) in operating liabilities:</u>				
Trade payables	-152.51		139.03	
Provision (CL)	-1.61		-48.07	
Borrowing (CL)	191.90		-50.45	
Other financial liabilities	0.00			
Other current liabilities	14.07		118.40	
Provison (NCL)	0.00			
<b>Cash generated from operations</b>		<b>-1.13</b>		<b>119.58</b>
Net income tax paid				
<b>Net cash flow from operating activities (A)</b>		<b>-1.13</b>		<b>119.58</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Capital expenditure on fixed assets, including capital advances	0.00		-169.95	
Investments	0.00		0.00	
Proceeds from sale of fixed assets/shares	15.00		0.00	
<b>Net cash (used in) / flow from investing activities (B)</b>		<b>15.00</b>		<b>-169.95</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds from issue of equity shares				
Finance costs	-106.02		-24.30	
Proceeds from Borrowings	69.79		600.00	
Payment of Borrowing	0.00		-497.66	
<b>Net cash flow (used in) financing activities (C)</b>		<b>-36.23</b>		<b>78.03</b>
<b>Net (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>-22.36</b>		<b>27.66</b>
<b>Cash and cash equivalents at the beginning of the year</b>		<b>28.43</b>		<b>0.77</b>
Effect of exchange differences on translation of foreign currency Cash and cash equivalents				
<b>Cash and cash equivalents at the end of the year</b>		<b>6.07</b>		<b>28.43</b>

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao  
Managing Director

Date: 29/05/2026  
Place:Hyderabad

**TRANSGENE BIOTEK LIMITED**

Notes forming part of the Consolidated financial statements

**Other expenses****(In Lakhs)**

<b>Particulars</b>	<b>For the Period ended on 31st March 2026</b>
Advertisement	0.13
Bank charges	0.00
BSNL Fiber net	0.02
Contractual expenses	0.27
Conveyance Expenses	0.06
Directors sitting fee	0.15
E Voting charges	0.17
Legal and Professional Charges	8.78
Miscllaneous Expenses	0.01
Municipal tax	2.46
Office Expenses	1.09
Postage and Courier Expenses	0.00
Printing and Stationary	0.00
Rates, taxes and duties	0.22
PCB Renewal	0.45
Telephone Expenses	0.02
Waste disposal Expenses	1.27
<b>Total</b>	<b>15.09</b>

**For TRANSGENE BIOTEK LIMITED****Dr.K.Koteswara Rao**  
**Managing Director****Date: 29/05/2026****Place:Hyderabad**